Home›Candesartan Cilexetil

Candesartan Cilexetil

Also known as: Atacand, Atacand HCT

Route: Oral

Check Candesartan Cilexetil Interactions →

8 interactions on record⛔ Black Box Warning

Candesartan Cilexetil has 8 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Aliskiren, Anakinra, Aspirin. Patients taking Candesartan Cilexetil should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 8
Contraindicated: 1
Major: 6
Moderate: 1

Contraindicated (1)

Candesartan Cilexetil + Aliskiren— Do not co-administer with candesartan cilexetil in patients with diabetes. Avoid use in patients with renal impairment (…

Major (6)

Candesartan Cilexetil + Anakinra— Triple combination with candesartan cilexetil and an ACE-inhibitor is generally not recommended due to increased risks o…
Candesartan Cilexetil + Aspirin— May result in deterioration of renal function, including possible acute renal failure, and may attenuate antihypertensiv…
Candesartan Cilexetil + Lithium— Increases in serum lithium concentrations and toxicity have been reported during concomitant administration. Monitor ser…
Candesartan Cilexetil + Magnesium Sulfate Heptahydrate— Coadministration may result in hyperkalemia. Monitor serum potassium in such patients.
Candesartan Cilexetil + Mao Inhibitors— May result in deterioration of renal function, including possible acute renal failure, and may attenuate antihypertensiv…
Candesartan Cilexetil + Potassium Supplements— Coadministration may result in hyperkalemia. Monitor serum potassium in such patients.

Moderate (1)

Candesartan Cilexetil + Candesartan— 7.3 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patient…

Candesartan Cilexetil + Aliskiren⛔Contraindicated

Do not co-administer with candesartan cilexetil in patients with diabetes. Avoid use in patients with renal impairment (GFR <60 ml/min). Associated with increased risks of hypotension, hyperkalemia, and renal dysfunction.

Candesartan Cilexetil + Anakinra⚠️Major

Triple combination with candesartan cilexetil and an ACE-inhibitor is generally not recommended due to increased risks of hypotension, hyperkalemia, and renal dysfunction.

Candesartan Cilexetil + Aspirin⚠️Major

May result in deterioration of renal function, including possible acute renal failure, and may attenuate antihypertensive effect. Risk increased in elderly, volume-depleted, or renal-compromised patients.

Candesartan Cilexetil + Lithium⚠️Major

Increases in serum lithium concentrations and toxicity have been reported during concomitant administration. Monitor serum lithium levels.

Candesartan Cilexetil + Magnesium Sulfate Heptahydrate⚠️Major

Coadministration may result in hyperkalemia. Monitor serum potassium in such patients.

Candesartan Cilexetil + Mao Inhibitors⚠️Major

Candesartan Cilexetil + Potassium Supplements⚠️Major

Coadministration may result in hyperkalemia. Monitor serum potassium in such patients.

Candesartan Cilexetil + Candesartan🟡Moderate

7.3 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including candesartan, may result in deterioration of renal function, including possible acute renal failure. Monitor renal function periodically in patients receiving candesartan and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including candesartan may be attenuated by NSAIDs including selective COX-2 inhibitors.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.